{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:30:07Z","timestamp":1772757007422,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/ftd.0b013e3181fa57fe","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T05:30:56Z","timestamp":1289367056000},"page":"757-761","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Cyamemazine on the Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: A Preliminary Retrospective Study"],"prefix":"10.1097","volume":"32","author":[{"given":"Fr\u00e9d\u00e9rique","family":"Lancelin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Bourcier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Le Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolande","family":"Lemeille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Brovedani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Paubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Liesse","family":"Piketty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-199448020-00009","article-title":"Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia.","volume":"48","author":"Grant","year":"1994","journal-title":"Drugs"},{"key":"R2-13-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4.","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"Suppl 5","key":"R3-13-20210129","first-page":"13","article-title":"The pharmacokinetics of risperidone in humans: a summary.","volume":"55","author":"Heykants","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R4-13-20210129","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s002130050010","article-title":"5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity.","volume":"147","author":"Alvarez-Guerra","year":"2000","journal-title":"Psychopharmacology"},{"key":"R5-13-20210129","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00213-005-2172-z","article-title":"A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).","volume":"180","author":"Hode","year":"2005","journal-title":"Psychopharmacology"},{"key":"R6-13-20210129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11096-006-9063-1","article-title":"Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study.","volume":"29","author":"Broekema","year":"2007","journal-title":"Pharm World Sci"},{"key":"R7-13-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejps.2007.09.003","article-title":"Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.","volume":"32","author":"Arbus","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"R8-13-20210129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.jcp.0000150234.99619.f3","article-title":"Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction.","volume":"25","author":"Nakagami","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R9-13-20210129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FTD.0b013e31818679c9","article-title":"Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.","volume":"30","author":"Mannheimer","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R10-13-20210129","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00007691-199612000-00018","article-title":"Thioridazine interferences with imipramine metabolism and measurement.","volume":"18","author":"Maynard","year":"1996","journal-title":"Ther Drug Monit"},{"key":"R11-13-20210129","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/00004714-199708000-00013","article-title":"The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients.","volume":"17","author":"Mulsant","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R12-13-20210129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00007691-200108000-00007","article-title":"Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.","volume":"23","author":"Suzuki","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R13-13-20210129","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0090-9556(24)15029-5","article-title":"Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.","volume":"27","author":"Shin","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"R14-13-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.euroneuro.2004.05.008","article-title":"Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms.","volume":"15","author":"Daniel","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R15-13-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology"},{"key":"R16-13-20210129","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2174\/1389450043345263","article-title":"The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions.","volume":"5","author":"Berecz","year":"2004","journal-title":"Curr Drug Targets"},{"key":"R17-13-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.","volume":"40","author":"De Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"R18-13-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hup.1025","article-title":"Effects of the CYP2D6*10 al10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.","volume":"24","author":"Yagihashi","year":"2009","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"R19-13-20210129","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","article-title":"Serum concentrations and side effects in psychiatric patients during risperidone therapy.","volume":"20","author":"Olesen","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R20-13-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-200208000-00014","article-title":"Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.","volume":"22","author":"Spina","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R21-13-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007691-200106000-00007","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.","volume":"23","author":"Spina","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R22-13-20210129","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-2005-837811","article-title":"Little effects of low dosage of levomepromazine on plasma risperidone levels.","volume":"38","author":"Yoshimura","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"R23-13-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.jcp.0000185428.02430.c7","article-title":"Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.","volume":"25","author":"Saito","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R24-13-20210129","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","article-title":"Inhibition and induction of human cytochrome P450 enzymes: current status.","volume":"82","author":"Pelkonen","year":"2008","journal-title":"Arch Toxicol"},{"key":"R25-13-20210129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2710.2000.00281.x","article-title":"Pharmacogenetics and psychopharmacotherapy.","volume":"25","author":"Poolsup","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"R26-13-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).","volume":"52","author":"Wen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R27-13-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate.","volume":"22","author":"Spina","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R28-13-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2007-958521","article-title":"Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.","volume":"40","author":"Yoshimura","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"R29-13-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology"},{"key":"R30-13-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200503000-00002","article-title":"Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.","volume":"20","author":"Kakihara","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"R31-13-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000054932","article-title":"Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.","volume":"44","author":"Yoshimura","year":"2001","journal-title":"Neuropsychobiology"},{"key":"R32-13-20210129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1082-6","article-title":"Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.","volume":"162","author":"Tauscher","year":"2002","journal-title":"Psychopharmacology"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181fa57fe","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:33:08Z","timestamp":1740681188000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201012000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181fa57fe","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}